Anixa Biosciences Inc cash flow statement

In fiscal 2024, Anixa Biosciences Inc's operations generated −$7.3m of cash; it spent $0 on capital projects, leaving free cash flow of −$7.3m. It returned $6,000 through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Anixa Biosciences Inc: cash flow statement, annual
Fiscal year	2010Oct 2010	2011Oct 2011	2012Oct 2012	2013Oct 2013	2014Oct 2014	2015Oct 2015	2016Oct 2016	2017Oct 2017	2018Oct 2018	2019Oct 2019	2021Oct 2021	2023Oct 2023	2024Oct 2024
Cash from operations	−2	−1	−3	−3	−2	1	−3	−4	−4	−5	−5	−6	−7
Depreciation and amortisation	0	0	0	—	—	0	0	0	0	0	—	—	—
Stock-based pay	1	2	1	3	2	3	—	−2	−9	−6	8	4	4
Capital spending	0	0	0	—	0	0	0	0	0	0	0	0	0
Free cash flow	−2	−1	−3	—	−2	1	−4	−4	−4	−5	−5	−6	−7
Free cash flow after stock pay	−3	−3	−4	—	−5	−1	—	−2	5	1	−12	−11	−12
Share buybacks	—	—	—	—	—	—	—	—	—	—	—	—	0
Shares issued	—	—	—	1	4	—	—	3	2	6	11	—	3

US$ thousands unless shown otherwise. Fiscal quarters.

Anixa Biosciences Inc: cash flow statement, quarterly
Quarter	2021 Q2Apr 2021	2021 Q3Jul 2021	2021 Q4Oct 2021	2022 Q1Jan 2022	2022 Q2Apr 2022	2023 Q2Apr 2023	2023 Q3Jul 2023	2023 Q4Oct 2023
Cash from operations	−1,242	−1,481	−1,045	−1,197	−2,306	−807	−1,445	−1,969
Stock-based pay	881	3,048	2,699	2,135	1,463	1,155	1,153	1,157
Capital spending	0	0	0	0	0	0	0	0
Free cash flow	−1,242	−1,481	−1,045	−1,197	−2,306	−807	−1,445	−1,969
Free cash flow after stock pay	−2,123	−4,529	−3,744	−3,332	−3,769	−1,962	−2,598	−3,126
Shares issued	5,218	0	−341	—	—	—	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Anixa Biosciences Inc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Anixa Biosciences Inc.